

FOI – 1971

2<sup>nd</sup> November 2023

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):**

- **Avelumab + Axitinib**
- **Axitinib**
- **Cabozantinib**
- **Everolimus**
- **Lenvantinib + Everolimus**
- **Nivolumab monotherapy**
- **Nivolumab + Cabozantinib**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Pembrolizumab monotherapy**
- **Pembrolizumab + Axitinib**
- **Pembrolizumab + Lenvatinib**
- **Radiotherapy only**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

**Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :**

- **Cobimetinib**
- **Dabrafenib**
- **Dabrafenib AND Trametinib**
- **Dacarbazine**
- **Denosumab**
- **Encorafenib AND Binimetinib**
- **Ipilimumab**
- **Ipilimumab AND Nivolumab**

- Nivolumab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

**Q3. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?**

**Response:**

Information is not held because neither of these cancers are treated in the Southern Health & Social Care Trust.

Email: [foi.team@southerntrust.hscni.net](mailto:foi.team@southerntrust.hscni.net)